CTLA4 and colitis: In this study, we aimed to describe the clinical, endoscopic, and histologic characteristics of a mono-institutional cohort of patients who developed diarrhea, colitis, or other GI AEs after treatment with anti–CTLA-4 or anti–PD-1/PDL1 drugs.